Your browser doesn't support javascript.
loading
Randomized, Placebo Controlled Trial of Experimental Hookworm Infection for Improving Gluten Tolerance in Celiac Disease.
Croese, John; Miller, Gregory C; Marquart, Louise; Llewellyn, Stacey; Gupta, Rohit; Becker, Luke; Clouston, Andrew D; Welch, Christine; Sidorenko, Julia; Wallace, Leanne; Visscher, Peter M; Remedios, Matthew L; McCarthy, James S; O'Rourke, Peter; Radford-Smith, Graham; Loukas, Alex; Norrie, Mark; Masson, John W; Gearry, Richard B; Rahman, Tony; Giacomin, Paul R.
Affiliation
  • Croese J; The Department of Gastroenterology and Hepatology, The Prince Charles Hospital, Brisbane, Australia.
  • Miller GC; Center for Molecular Therapeutics, Australian Institute of Tropical Health and Medicine, James Cook University, Cairns, Australia.
  • Marquart L; Envoi Specialist Pathologists, Brisbane, Australia.
  • Llewellyn S; QIMR Berghofer Medical Research Institute, Brisbane, Australia.
  • Gupta R; QIMR Berghofer Medical Research Institute, Brisbane, Australia.
  • Becker L; Center for Molecular Therapeutics, Australian Institute of Tropical Health and Medicine, James Cook University, Cairns, Australia.
  • Clouston AD; Center for Molecular Therapeutics, Australian Institute of Tropical Health and Medicine, James Cook University, Cairns, Australia.
  • Welch C; Envoi Specialist Pathologists, Brisbane, Australia.
  • Sidorenko J; Department of Gastroenterology, Townsville University Hospital, Townsville, Australia.
  • Wallace L; Institute for Molecular Bioscience, The University of Queensland, Brisbane, Australia.
  • Visscher PM; Institute for Molecular Bioscience, The University of Queensland, Brisbane, Australia.
  • Remedios ML; Institute for Molecular Bioscience, The University of Queensland, Brisbane, Australia.
  • McCarthy JS; Department of Gastroenterology and Hepatology, Royal Brisbane and Women's Hospital, Brisbane, Australia.
  • O'Rourke P; QIMR Berghofer Medical Research Institute, Brisbane, Australia.
  • Radford-Smith G; QIMR Berghofer Medical Research Institute, Brisbane, Australia.
  • Loukas A; QIMR Berghofer Medical Research Institute, Brisbane, Australia.
  • Norrie M; Center for Molecular Therapeutics, Australian Institute of Tropical Health and Medicine, James Cook University, Cairns, Australia.
  • Masson JW; Gastroenterology and Hepatology, Logan Hospital, Brisbane, Australia.
  • Gearry RB; Department of Gastroenterology, Townsville University Hospital, Townsville, Australia.
  • Rahman T; Department of Medicine, University of Otago, Christchurch and Canterbury District Health Board, Christchurch, New Zealand.
  • Giacomin PR; The Department of Gastroenterology and Hepatology, The Prince Charles Hospital, Brisbane, Australia.
Clin Transl Gastroenterol ; 11(12): e00274, 2020 12.
Article in En | MEDLINE | ID: mdl-33512796
INTRODUCTION: Celiac disease is an autoimmune disorder where intestinal immunopathology arises after gluten consumption. Previous studies suggested that hookworm infection restores gluten tolerance; however, these studies were small (n = 12) and not placebo controlled. METHODS: We undertook a randomized, placebo-controlled trial of hookworm infection in 54 people with celiac disease. The 94-week study involved treatment with either 20 or 40 Necator americanus third-stage larvae (L3-20 or L3-40) or placebo, followed by escalating gluten consumption (50 mg/d for 12 weeks, 1 g intermittent twice weekly for 12 weeks, 2 g/d sustained for 6 weeks, liberal diet for 1 year). RESULTS: Successful study completion rates at week 42 (primary outcome) were similar in each group (placebo: 57%, L3-20: 37%, and L3-40: 44%; P = 0.61), however gluten-related adverse events were significantly reduced in hookworm-treated participants: Median (range) adverse events/participant were as follows: placebo, 4 (1-9); L3-20, 1 (0-9); and L3-40, 0 (0-3) (P = 0.019). Duodenal villous height:crypt depth deteriorated similarly compared with their enrolment values in each group (mean change [95% confidence interval]: placebo, -0.6 [-1.3 to 0.2]; L3-20, -0.5 [-0.8 to 0.2]; and L3-40, -1.1 [-1.8 to 0.4]; P = 0.12). A retrospective analysis revealed that 9 of the 40 L3-treated participants failed to establish hookworm infections. Although week 42 completion rates were similar in hookworm-positive vs hookworm-negative participants (48% vs 44%, P = 0.43), quality of life symptom scores were lower in hookworm-positive participants after intermittent gluten challenge (mean [95% confidence interval]: 38.9 [33.9-44] vs 45.9 [39.2-52.6]). DISCUSSION: Hookworm infection does not restore tolerance to sustained moderate consumption of gluten (2 g/d) but was associated with improved symptom scores after intermittent consumption of lower, intermittent gluten doses.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Celiac Disease / Necator americanus / Therapy with Helminths / Glutens / Larva Type of study: Clinical_trials Aspects: Patient_preference Limits: Adolescent / Adult / Aged / Aged80 / Animals / Female / Humans / Male / Middle aged Language: En Journal: Clin Transl Gastroenterol Year: 2020 Document type: Article Affiliation country: Australia Country of publication: United States

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Celiac Disease / Necator americanus / Therapy with Helminths / Glutens / Larva Type of study: Clinical_trials Aspects: Patient_preference Limits: Adolescent / Adult / Aged / Aged80 / Animals / Female / Humans / Male / Middle aged Language: En Journal: Clin Transl Gastroenterol Year: 2020 Document type: Article Affiliation country: Australia Country of publication: United States